Aggregation of throbocytes as a marker of efficiency and safety of antiplatelet therapy in patient with ischemic heart disease
Residual platelet reactivity (RPR) was studied as a marker of effectiveness and safety of antiplatelet therapy in patients with chronic and acute forms of ischemic heart disease (IHD). 1 02 patients with various forms of IHD and various combinations of anti-platelet therapy were taken into the study. Their platelet function was tested with optical transmission aggregatometry. As it has been shown, the discussed technique can be used for personified antiplatelet therapy and can prevent its ischemic and hemorrhagic complications.